Mehul Choksi accuses authorities of violating natural justice, seeks fresh relief
He further contends that the authorities not only disregarded due process but also violated his fundamental rights, contravening the principles of natural justice.
The fugitive diamond merchant has demanded his immediate release, citing procedural irregularities. This development comes just days after the Belgian Court of Appeal rejected his bail plea in the same case.
Mehul Choksi, in his second plea before the Belgian court, has claimed that the process undertaken regarding his arrest is arbitrary and unlawful. This is the second plea made by Mehul Choksi before the court after his earlier plea seeking release (bail) was rejected by the Court last week. The next date for the hearing has not yet been notified.
A court in Belgium last week denied the bail plea of Mehul Choksi, a key accused in the Rs 13,500 crore Punjab National Bank loan fraud case. A three-judge bench heard arguments in Dutch before ruling against granting bail. Choksi was arrested in Belgium earlier this month following an official request from Indian authorities.
His lawyer, Vijay Aggarwal, was seen in Antwerp ahead of the bail hearing and later met Choksi in jail. Speaking to ANI, Vijay Aggarwal expressed disappointment over the court's decision but noted that Belgian law allows multiple bail applications.
"Unfortunately, my client has been denied bail today. However, in Belgium, we can apply for bail as many times as needed. We will carefully consider the court's observations and submit a fresh bail plea on new grounds soon", he said.
Aggarwal also reiterated that the legal team would contest his extradition on two main grounds--the political nature of the case and concerns regarding his medical condition and treatment in India. He earlier stated that Choksi has cooperated with Indian investigative agencies and has repeatedly offered to join the investigation via video conferencing due to his health issues.
The legal team earlier also pointed out procedural prerequisites for extradition, including the issuance of non-bailable warrants since 2018. Aggarwal noted that previous attempts to extradite Choksi from Dominica had failed, and Choksi had been receiving medical treatment in Antigua before travelling to Belgium for cancer care.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Observer
4 hours ago
- Observer
Crude holds strong amid OPEC+ hike
Brent crude prices held steady above $68 per barrel on Tuesday after a three-day decline, while WTI hovered around $65.25, with both benchmarks slipping 0.25%, according to Vijay Valecha, Chief Investment Officer, Century Financial. This recent bearish trend reflects mounting fears of a potential supply surplus due to OPEC+'s decision to increase output, even as uncertainties persist over Russian oil agreed to raise production by 547,000 barrels per day in September, reversing the 2.2 million bpd cut implemented by eight member states in 2023. This move has added downward pressure on prices amid heightened geopolitical tensions. Meanwhile, President Donald Trump announced plans to significantly increase tariffs on Indian exports, citing India's continued purchases of Russian oil, a proposal that would raise tariffs above the current 25% and further strain global trade relations, contributing to oil market volatility. Nevertheless, seasonal summer demand continues to lend short-term support. Technically, WTI crude is testing a key upward trendline, with a decisive close below this level potentially opening the way for further declines toward the 100-day SMA at $64.40. If support holds, a rebound toward the 21-day SMA at $66.30 is possible. Brent faces resistance near its 21-day SMA at $69, with support at the 100-day SMA around $67.35. These technical levels will be pivotal for determining the near-term direction, but overall, crude oil may remain under pressure for now.
Observer
3 days ago
- Observer
India reels from the shock of Trump's onslaught
NEW DELHI — President Donald Trump's new list of tariffs on half the world's countries sent the United States' trading partners scrambling to understand how their businesses will be affected. India got the bad news a day earlier — its goods face a tariff of 25% or more — but the extra time was hardly enough to adjust to the fresh chaos. Indian negotiators had not expected to conclude a meaningful deal in time to meet Trump's revised deadline of Aug. 1. But they did expect to be treated as well as their neighbors, and to keep haggling with U.S. officials until October or November, when Trump was invited to visit India as part of the Quad defense group, which brings together four big democracies — India, the United States, Japan and Australia — with a shared interest in standing up to China. Instead, they were fed a heap of insults and injuries. Along with the 25% rate, one of the highest in Asia and only a point lower than what was threatened on 'Liberation Day' in April, India was informed that its existing trade barriers are 'strenuous and obnoxious'; it will be charged an untold penalty for buying Russian oil; it is a 'dead economy.' It's archrival Pakistan was praised and promised an oil exploration deal. Hurt feelings aside, the results are confusing. Two of the biggest categories of exports to the United States from India are personal electronics, worth about $14 billion a year, and pharmaceuticals, worth $10 billion. Rajesh Sharma, executive director of India Cellular and Electronics Association, said smartphones were exempted from these tariffs; so did executives at pharmaceutical companies. But on Friday, after reading the executive order, the Global Trade Research Initiative in New Delhi concluded the opposite. India's stock markets dipped on the news for two days running. Indian and international banks wrote notices warning that the country's generally hard-charging economic growth is likely to slow measurably as a result of the tariffs. Then there are the unknown tariffs. On July 6, Trump wrote that countries aligned with the BRICS group, of which India is a founding member, would incur an additional 10% penalty. Then on July 14, he said that, if Russia didn't make peace with Ukraine within 50 days, he would punish its trading partners with 'secondary tariffs' of 100%. That figure is making Indians worry anew. Trump added 'plus a penalty' to the 25% rate imposed on India, for buying Russian oil and weapons. Shashi Tharoor, a prominent member of the opposition, spoke to an Indian news agency about the possible impact. 'There's even talk of a 100% penalty,' he said, 'which will destroy our trade with America.' There is evidence that Indian buyers of Russian oil were already pulling back before the executive order. 'Indian refiners have reduced Russian crude purchases this week,' said Sumit Ritolia, an analyst at Kpler, which tracks shipping and commodities. They were already 'looking to further diversify, amid rising concerns over potential U.S. sanctions,' having spent years taking advantage of discounted Russian oil to reduce their imports from the Persian Gulf. Reducing the United States' trade deficit is one of the Trump administration's goals, so persuading India to buy more American oil and gas would make sense. Last year, India exported $45.7 billion more goods to the United States than it imported. It spent about three times as much importing oil. If a third of that were redirected to American sources, their bilateral trade would be evened out. Trump's angry barrage of social media has complicated further negotiations. The breakdown of trust between Narendra Modi, India's prime minister, whom Trump called his 'true friend,' the U.S. president is likely to make it harder to complete any deal, analysts say. Indian news outlets have reported that Trump wanted to iron out some outstanding issues, after four rounds of direct talks between the two sides, in a phone call with Modi. The Indian government was anxious to avoid any of his last-minute surprises. The U.S. commerce secretary accused India of 'slow-rolling' its trade negotiations. Indian officials and analysts say the friction is caused by a fundamental difference of approach. Trump has a penchant for quick, top-down dealmaking. India's bureaucracy moves at a methodical pace, especially when it comes to opening up the agriculture market, which is politically sensitive. India's recently concluded trade deal with Britain took three years of talks, under two British prime ministers. On Friday, India's Foreign Ministry released a statement that put on a brave face. 'India and the United States share a Comprehensive Global Strategic Partnership,' established in 2013 between President Barack Obama and then-Prime Minister Manmohan Singh, 'anchored in shared interests, democratic values and robust people-to-people ties.' The ministry stuck to principles, revealing no plan for breaking through Trump's hard line. 'This partnership has weathered several transitions and challenges,' the statement said. 'We remain focused on the substantive agenda that our two countries have committed to and are confident that the relationship will continue to move forward.' This article originally appeared in
Times of Oman
4 days ago
- Times of Oman
Pharma businesses ready with contingency plans faced with US tariffs: Association of Healthcare Providers (India)
New Delhi: Indian pharmaceutical manufacturers are preparing a two-pronged strategy to offset the impact of the soon-to-be-effective 25 per cent US tariff on Indian goods, which includes drug exports, with industry experts anticipating that the move could significantly raise medicine costs in the American market. Girdhar Gyani, Director General of the Association of Healthcare Providers (India), has voiced concern over the financial burden the proposed US tariff would impose on both Indian exporters and American consumers. India currently supplies around 47 per cent of the US pharmaceutical market, largely in the form of affordable generics. "If the United States enforces this 25 per cent tariff, the cost of drug delivery in the US will inevitably rise. Our estimates show that American drug prices could increase by 20 to 25 per cent annually -- a burden of nearly USD 6 to USD 7 billion. It's unclear whether the US healthcare system can absorb such an impact," Gyani said. According to its website, the Association of Healthcare Providers (India) , a non-profit organisation, represents the majority of healthcare providers in India. Despite the initial blow to Indian manufacturers, Gyani stated that industry players are already preparing contingency plans. One such measure is ramping up production in US-based and Mexico-based facilities owned by Indian firms, which, according to Gyani, would bypass the tariff restrictions. "The second approach involves a shift in focus from basic generics to value-added combination drugs. These combination drugs, which offer the convenience of two medicines in one, can be priced higher despite having similar production costs," he noted. The goal is to increase the volume and price range of such drugs, thereby maintaining competitiveness even under the new tariff regime. Gyani also suggested that continued diplomatic engagement between New Delhi and Washington could help mitigate the situation. "Negotiations between the two governments are likely to continue, and we may eventually see a reduction or reconsideration of the tariff policy," he said. The executive order signed by President Donald Trump on Thursday has imposed a flat 25 per cent tariff on all goods from India, with no product-level exemptions. The pharmaceutical sector has been a key pillar of India-US trade relations.
